However, unlike the cases of prostate specific antigen (PSA) for prostatic cancer and α-fetoprotein (AFP) for liver cancer, up to now, there was no biomarker available for early warning of breast cancer in clinical practice except that invasive genetic test of BRCA1/2 mutation was recommended to evaluate the risk of hereditary breast cancer [39]. Here, BRCA1 is linked to prostate carcinoma.